A novel immunotherapy may offer hope for blood cancer patients with no previous options. PeproMene Bio's BAFF-R CAR-T treatment is showing promising results with no side effects.
Novel cellular immunotherapy has shown a promising outcome for patients who have experienced relapses in blood cancers, according to new clinical data by PeproMene Bio.
Korea JoongAng Daily Sitemap
